PMPRB Update Pharma Symposium Canada March 31, 2015.
23
PMPRB Update Pharma Symposium Canada March 31, 2015
-
Upload
roderick-jennings -
Category
Documents
-
view
219 -
download
0
Transcript of PMPRB Update Pharma Symposium Canada March 31, 2015.
PMPRB UpdatePharma Symposium CanadaMarch 31, 2015
Canadian pricing and reimbursement regime
Canada is the only developed country in the world with a universal public health insurance program that excludes coverage for prescription drugs.
As such, Canada is fairly unique in that it does not have a national pharmaceutical negotiator and formulary for its population.
Federally, the PMPRB reviews patented drugs and sets price ceilings based on level of therapeutic improvement, domestic prices and prices in the “PMPRB7”.*
At the provincial level, CADTH reviews drugs for therapeutic benefit and cost effectiveness and makes reimbursement recommendations to participating public payers.
2
Pricing and reimbursement (continued)
Provincial and territorial health ministries negotiate prices directly with manufacturers, either individually or under the auspices of the pCPA.
Private insurers manage employer-sponsored drug plans and also negotiate prices with
manufacturers, but wield less purchasing power than provinces.
Uninsured Canadians (mainly the working poor) pay for prescription drugs at “list” prices.
One in ten Canadians said to be unable to afford to fill their prescriptions (CMAJ 2012).
3
Payer Share of drug costs
Public insurance 42%
Private insurance 35%
Out-of-pocket (uninsured) 23%
Pharmaceutical Regulation in Canada is Shared
4
PMPRB Jurisdiction covers patented drug products sold in Canada, whether through market approval or
under Health Canada’s Special Access Program (SAP)
Market Approval
Health Canada Review For Safety, Efficacy & Quality
Health Canada Post-Market Surveillance
Over Life of Patent(s)
Public Drug Plan Reimbursement
Private Drug Plan Reimbursement
CADTH Common Drug Review
Individual Federal/Provincial Public Drug Plan Listing
Drug share of total health spending (2012)
5
Drugs are the second/third (depending on year) largest health cost for Canada, but they are by far the largest health cost for uninsured Canadians .
Hospitals
29%
Physicians15%
Other Institutions10%
Other
Professionals10%
Other6%
Public Health5%
Capital5%
Admin
3%
Prescription 14%
Non-prescription 2%Total Canadian
Hospitals3% Physicians
2%
Other In-sti-tu-tions
20%
Other
Professionals
32%
Other4%
Prescription22%
Non-prescription17%
Out-of-pocket (uninsured)
PMPRB 101
The PMPRB is an independent, quasi-judicial consumer protection agency with a regulatory and reporting mandate.
We are 60 civil servants on “staff” and 5 Cabinet-appointed Board members.
On the regulatory side, staff review patented drug prices to ensure they are not excessive as per the Patent Act and corresponding Regulations and Guidelines.
Where staff considers the price of a drug to be excessive, a patentee can agree to pay back excess revenues and/or lower its price through a voluntary settlement (VCU).
If the patentee refuses a VCU, a hearing will be held before a panel of Board members if the Chairperson considers it in the public interest.
If the panel decides a drug is excessively priced, it can order the patentee to reduce its price and/or pay back excess revenues.
6
Regulatory mandate
At intro, a drug’s price ceiling is set based on its category of therapeutic improvement, the price of domestic comparators and its price elsewhere in the PMPRB7.*
Four therapeutic categories, with descending price ceilings (in theory):
1. Breakthrough 2. Substantial Improvement3. Moderate Improvement4. Slight/No Improvement
After introduction, an existing drug is eligible for CPI-based price increases.
At no time can a drug’s price exceed the highest in the PMPRB7 (HIPC rule).
* France, Germany, Italy, Sweden, Switzerland, the UK and the US.
7
8
Annual Report Analysis of prices of patented drugs, price trends of all drugs, and R&D spending: http://
www.pmprb-cepmb.gc.ca/en/reporting/annual-reports
National Prescription Drug Utilization Information System (NPDUIS) Established in 2001 as an F/P/T research initiative to provide policy makers and drug
plan managers with analyses of price, utilization and cost trends
The NPDUIS Advisory Committee advises the PMPRB and provides expert oversight and guidance for the analytical reporting of the initiative
The Committee is composed of BC, AB, SK, MB, ON, NB, NS, PEI, NL, YK, NIHB & HC, CIHI and CADTH.
Reporting mandate
9
Reports published in 2014/15 CompassRx, 2012-13 Generic Drugs in Canada, 2013 – December 11, 2014 New Drug Pipeline Monitor, 6th edition – December 2013 Utilization of Prescription Opioids in Canada's Public Drug Plans, 2006/07 to 2012/13 – April 2014
Research agenda Private Drug Plans in Canada: Generic Drug Market, 2013 International Retail Price Comparison, 2013 Compass Rx, 2013-14 Private Drug Plans in Canada: Cost Driver Analysis, 2013 Utilization and Cost of Biologics, 2005/06 to 2012/13 Private Drug Plans in Canada: High-Cost Drugs, 2013 New Drug Launch Monitor, 2014 New Drug Pipeline Monitor, 7th edition
NPDUIS
10
New NPDUIS flagship report
Comprehensive analysis of cost drivers in public drug plans:
• Price effects• Demographic effects• Volume effects• Drug-mix effects
Release date is today!
http://www.pmprb-cepmb.gc.ca/
11
Compass Rx – “push-pull” drug spending effect
Demographic
Volume
Drug-Mix
Price change
Generic Subs
Although net growth in drug spending has been low in recent years because of the “pull effect” of increased generic substitution and generic price reductions, that phenomenon appears to have run its course.
In the coming years, the cost drivers behind the “push effect” are expected to pose a challenge to the sustainability of both public and private drug plans, for example, in 2014:
Spending on high cost biologics grew by 10.4%;
Spending on high cost oncology drugs grew by 12.3%.
Total Push Effects 8.5%
Total Pull Effects -9.2%
12
Has Canada already turned the corner?
Source: IMS Brogan. Canadian Drug Stores and Hospitals Purchases, MAT December 2014
2009 2010 2011 2012 2013 2014
-10.0%
-5.0%
0.0%
5.0%
10.0%
15.0%
6.5%
1.7%
-0.9
%
0.0% 0.
6%
4.4%5.
0%
-0.5
%
0.6%
0.2%
1.8%
5.6%
11.6
%
8.6%
-5.2
%
-0.6
%
-3.4
%
0.6%
Canadian Drug Spending Growth Rate
Total Market Brands Generics
Year
ove
r yea
r gro
wth
rate
13
Latest data on drug-mix effect
Source: IMS Brogan. Canadian Drug Stores and Hospitals Purchases, MAT December 2014
2007 2008 2009 2010 2011 2012 2013 20140
50
100
150
200
250
300
350
0
2
4
6
8
10
12
High-cost product launches
Total Spending Per Product Launched
Spen
ding
on
New
Acti
ve S
ubst
ance
s (m
illio
n C$
)
Spen
ding
per
Pro
duct
Laun
ched
(mill
ion
C$)
14
Source: IMS MIDAS, 2013
Canada’s performance is not strong within PMPRB7…
France Switzerland Sweden Germany Italy UK Canada US0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
3.5%
4.0%
4.5%
5.0%
1.0%
2.6%
2.9%
3.2%3.4%
3.7% 3.8%
4.3%
PMPRB7 Drug Sales (AGR 2005-2013)Av
erag
e Gr
owth
Rat
e (%
per
yea
r)
15
MexicoIsrael
DenmarkNew Zealand
EstoniaPoland
UKLuxembourg
NorwayCzech Rep
NetherlandsKorea
PortugalFinlandSwedenIceland
SloveniaSpain
SlovakiaAustria
SwitzerlandHungaryAustralia
FranceGermany
JapanBelgiumCanada
USA
$0 $200 $400 $600 $800 $1,000 $1,200
$70$274
$295$297
$311$321
$367$399
$414$439$450$454
$473$473$478
$512$513$523
$535$561$562
$574$588
$651$668
$718$736
$771$1,010
Drug Expenditure (PPP/c), OECD 2012OECD Average: $498
Source: OECD, 2012
… nor within the OECD
16
France UK Italy Sweden Switzerland Canada Germany US0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
2.00
2.25
0.99
1.11
0.88
1.05
1.21
1.00
1.15
1.83
0.720.78 0.79
0.900.95
1.00 1.04
2.07
Average PMPRB7-to-Cdn Price Ratios
20052013
… and price is clearly a contributing factor
Why are prices going down in other countries?
17
Country Year Type of ReformUK 2014 Annual, per company, public expenditure ceilings – 0% growth for next two years.
Sweden 2014 7.5% price reduction for drugs >15 years old not subject to generic competition.
Switz 2013 Legislated negotiated price reduction of 2500 drugs.Italy 2013 Expenditure ceiling, performance based reimbursement, 2-year price re-evaluation.
France 2012 Mandatory price review every 5 years, reimbursement rates cut for low innovation medicines, new stringent therapeutic evaluations.
Germany 2011 Consolidation of regulatory roles, mandatory rebates to public plans.
Over the 2010-2012 period, 23 European countries began planning or executed a major reform of their pharmaceutical price regulatory framework.
Germany: impact of AMNOG
18
2005 2006 2007 2008 2009 2010 2011 2012 20130.90
0.95
1.00
1.05
1.10
1.15
1.20
1.25
Germany-to-Canada Drug Price Ratio
Canada
2011 “AMNOG” reform is expected to save €2 billion per year and has already reduced the price of the 25 top-selling brand drugs by an average of 23%.
19
Canada All Comparators France Germany Italy Sweden Switzerland UK US0%
20%
40%
60%
80%
100%
120%
140%
10.1
% 20.4
%
16.8
%
17.3
%
6.2%
44.4
%
102.
5%
35.1
%
18.4
%
5.6%
21.7
%
17.4
%
20.4
%
6.2%
25.3
%
126.
2%
40.5
%
19.4
%
R&D-to-Sales Ratio, Canada and PMPRB7
20002011
As prices go up, R&D is going down
Why is this happening?
R&D
Evidence does not support purported link between price, IP and R&D.
Other factors, such as head office location, science base, clinical trial infrastructure, population density, etc. appear to be better predictors of locus of pharmaceutical R&D
Price
As noted, EU countries are taking aggressive action to control drug costs.
No national purchasing authority in Canada, and key decisions impacting price are made independently of one another by different F/P/T players.
PMPRB regime not keeping up with international or industrial trends.
20
21
Payers are concerned about sustainability
“The (provincial drug plan) programs are starting to face extreme financial constraints. The growth that we’re seeing in some categories of drugs is far beyond what were ever anticipated four or five years ago.”
– Fred Horne, Alberta Minister of Health, speaking at April 7, 2014 CADTH symposium
“We’re now at a point where ongoing sustainability of meaningful prescription drug coverage is threatened for a vast number of Canadians. In the past few years alone, the number of very-high-cost medications for genetic disorders, cancer and auto-immune diseases has increased substantially -- and this trend is expected to continue.
– Frank Swedlove, President of CLHIA, speaking at the October 30, 2013 Conference Board 2nd Summit on Sustainable Health Care
What’s next for the PMPRB?
In 1987, Canada signalled its willingness to pay its “fair share” of international drug development costs with enactment of present day drug patent policy – Bill C-22.
Bill C-22 also created PMPRB as consumer protection “pillar” of that policy.
PMPRB7 selected on basis of assumption that by offering comparable “fair” prices and patent rights, Canada would come to “emulate” R&D levels in these countries.
With Canadian prices approaching second highest of PMPRB7 and R&D at record lows, that assumption now being questioned, as is relevance of PMPRB.
Timing opportune for fresh look at PMPRB framework in light of current CETA changes, sustainability concerns and GoC priorities (eg. price gap, defending consumers).
PMPRB to publish new three year strategic plan in spring 2015 – stay tuned…
22
